**Abstract**

**Objective:** Depressive disorders typically emerge during early adolescence and adulthood, and if left untreated, increase risk of chronicity, morbidity and mortality. Pharmacotherapy with selective serotonin reuptake inhibitors (SSRIs) is first-line treatment, though increased risk of suicidality with SSRI use in youth populations is cautioned in the literature. Escitalopram is a newer SSRI with superior efficacy and tolerability to other SSRIs, but without data specifically in early depression patients. The aim of this study was to investigate the efficacy, safety and tolerability of escitalopram monotherapy in young adult patients with first-episode depression.

**Methods:** Forty-two (42) patients, 18--29 years, medication-free and diagnosed with first-episode depression, were recruited. Open-label escitalopram was administered for 16 weeks at flexible dose (5--30 mg/day). The primary efficacy measure was the 17-item Hamilton Depression Scale (HAMD-17). The secondary efficacy measures were the Beck Depression Inventory (BDI) and the Neo Personality Inventory (NEO-PI-R). All measures were completed at baseline, 8 weeks and 16 weeks. Safety and tolerability were assessed via questioning at each patient visit.

**Results:** Between baseline and 16 weeks, there was a significant decrease in depression scores on the HAMD-17 (p\<0.001) and BDI (p\<0.0001). On the NEO-PI-R, there was a significant decrease in neuroticism (p=0.003), and significant increase in extraversion (p=0.0002) and openness to experience (p\<0.0001). The response rate was 77% and the remission rate was 64%. The mean dose at 16 weeks was 19.05 mg/day, with no significant difference between responders and non-responders (p=0.06). Side effects reported were mild, consisted mainly of dry mouth and nausea, and did not lead to discontinuation.

**Conclusions:** Open-label escitalopram was effective in improving both symptoms and functioning in young adults with first-episode depression. It was also well tolerated. Limitations include lack of placebo control, non-randomized design and small sample size.
